title: Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
abstract: OBJECTIVE
  To assess the efficacy and safety of switching patients from bilateral latanoprost to bimatoprost in 1 eye while maintaining latanoprost in the fellow eye.
  
  
  METHODS
  This prospective, open-label, multicenter, uniocular (within-eye control) study was conducted from March 2005 to February 2007; 105 patients with glaucoma or ocular hypertension were enrolled. At baseline, patients using bilateral latanoprost were switched to bimatoprost treatment in 1 eye (study eye) and continued latanoprost treatment in the fellow eye (control eye). At 12 weeks, patients were offered bilateral bimatoprost for 12 additional weeks.
  
  
  RESULTS
  At week 12, the mean difference in intraocular pressure (IOP) from baseline was -3.0 mm Hg in study eyes and -1.6 mm Hg in control eyes, which equates to a further -1.4 mm Hg (95% confidence limits: -1.9, -0.9) reduction in IOP in study eyes compared with control eyes (P<0.0001). Overall, 27% (28/104) more study eyes had > or = -2.5 mm Hg reduction in IOP than control eyes (P<0001). At week 24, the mean difference in IOP from baseline was -2.8 mm Hg for study eyes and for control eyes that had switched to bimatoprost. Conjunctival hyperemia occurred more frequently and was more severe in bimatoprost-treated eyes at week 12 than at baseline (P<0.001). No patients withdrew from treatment because of conjunctival hyperemia.
  
  
  CONCLUSIONS
  Clinically, these data suggest that switching patients from latanoprost to bimatoprost may result in further improvement in IOP control.
authors.affiliation: South Australian Institute of Ophthalmology, University of Adelaide, Adelaide, South Australia 5000, Australia. robert.casson@adelaide.edu.au
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Casson
authors.forename: Lance
authors.initials: L
authors.lastname: Liu
authors.forename: Stuart L
authors.initials: SL
authors.lastname: Graham
authors.forename: William H
authors.initials: WH
authors.lastname: Morgan
authors.forename: John R
authors.initials: JR
authors.lastname: Grigg
authors.forename: Anna
authors.initials: A
authors.lastname: Galanopoulos
authors.forename: Andrew
authors.initials: A
authors.lastname: Crawford
authors.forename: Philip H
authors.initials: PH
authors.lastname: House
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003229:Conjunctival Diseases / Q000139:chemically induced; D018592:Cross-Over Studies; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000577:Amides; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost